Progress and Promise in the Treatment of Indolent Lymphomas

Open Access
Publisher Website
Google Scholar
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe subsets of patients with indolent lymphoma for whom cure may be a realistic goal. Describe the ways by which the polymerase chain reaction for bcl-2 can be utilized to monitor patients with follicular lymphoma. Identify immunotherapy approaches that have shown promising results for patients with indolent lymphoma. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com In the era of conventional alkylating agent-based chemotherapy, advanced stage indolent lymphoma has been considered incurable. The failure of our traditional therapies to cure these patients, coupled with the indolent course of the disease and the elderly population affected, has fostered a nihilistic attitude about the treatment of these diseases. Twenty years ago, in the absence of interesting alternatives to alkylating agents, judicious use and reuse of alkylators was perhaps the best we could do. There are now many reasons for optimism and excitement in the treatment of these diseases, including the availability of promising agents such as interferon-α, the nucleoside analogues, and rituximab. Radioimmunotherapy will also likely play a role in future therapy programs. Allogeneic stem cell transplantation is a high-risk approach that is not an option for all patients, but it has the potential to cure patients, even in the setting of relapse. Mini-allogeneic transplantation may permit an approach to allogeneic transplantation that is better tolerated than standard transplant strategies. In addition to these therapy options, biological insights have provided new options for monitoring patients. Molecular monitoring (polymerase chain reaction for bcl-2) is a stringent measure of short-term treatment efficacy, and one that correlates with durability of remission, i.e., it is a surrogate marker by which to judge treatment efficacy. There used to be a limited number of conventional treatment approaches, which consistently failed. The pendulum has swung. There are now many promising new options. It is time to plan and conduct trials that are geared for success.
Funding Information
  • National Cancer Institute (CA16672)
  • The University of Texas M.D. Anderson Cancer Center

This publication has 58 references indexed in Scilit: